| Name | Title | Contact Details |
|---|
Mazars is an internationally integrated partnership, specialising in audit, accountancy, advisory, tax and legal services*. Operating in over 100 countries and territories around the world, we draw on the expertise of more than 50,000 professionals – 33,000+ in Mazars integrated partnership and 17,000+ via the Mazars North America Alliance – to assist clients of all sizes at every stage in their development. *Where permitted under applicable country laws
Our agency is the vision of a small group of insurance professionals who have spent years building large and mid-level risk management agencies. Mythic was born out of their desire to build an agency that caters to a select group of long-term clients who have an investment-minded view and value creativity and flexibility in a business partner. Although we have developed large specialty programs, such as our franchisor/franchisee risk management solution, we relish any opportunity to creatively craft custom risk management programs that mold to a clients specific needs. We offer expert guidance and flexibility to our clients, adjusting as their needs change and grow over time. Our ultimate goal is to make risk management and insurance profitable and as painless as possible.
With headquarters in the greater St. Louis region, UNCOMN provides Industry-Leading B2B Management and Technology Consulting Services. We are a diverse group of engineers, architects, analysts, hackers, and geeks who thrive on finding elegant solutions to wickedly complex organizational, logistic, process, data, and technical problems. In everything we do, we pursue truth, goodness, and beauty. We put people first and hire for the long-term, not for the contract. We put the right people in the right roles. We work with rigor, transparency, and excellence – doing whatever it takes while upholding unquestionable integrity, from start to finish. And we do so with the intention of making our team, clients, and communities better along the way. At UNCOMN, we arent just about profits and the bottom line. We uphold service before self, giving over receiving and social impact over siloing. Its our duty as industry experts to lead by example, share what we know and help create strong, vibrant communities in which we are proud to live and serve. We invest in and mentor for SixThirty CYBER, a business development program that offers cyber security-based technology startups with up to $250,000 of services each year. Through these services, the St. Louis regions top executives and chief information security officers provide hands-on training, mentoring and network opportunities to the startups key stakeholders.
Arch Insurance Group Inc., a division of Arch Capital Group Ltd. (ACGL), is a market-leading specialty insurer. We provide a wide range of property, casualty and specialty insurance for corporations, professional firms and financial institutions across the United States and Canada. Our insurance group in North America consists of Arch Insurance Company, Arch Specialty Insurance Company and Arch Excess & Surplus Insurance Company. Arch Insurance Groups executive offices are located at One Liberty Plaza in New York City, with regional offices located in New York City (Northeast Region), Atlanta (Southeast Region), Chicago (Central Region) and San Francisco (Western Region), as well as other offices throughout the U.S. to support our business. Arch Insurance Company also operates a branch office in Toronto, Canada. ACGL is a Bermuda public limited liability company that provides insurance, reinsurance and mortgage insurance on a worldwide basis through operations in Bermuda, the United States, Canada, Europe, Australia and Hong Kong.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.